(Q42289226)

19 October 2017

title

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus (English)

1 reference

19 October 2017

1 reference

1 reference

19 October 2017

Boucher FD

1 reference

19 October 2017

Modlin JF

1 reference

19 October 2017

Weller S

1 reference

19 October 2017

Ruff A

1 reference

19 October 2017

Mirochnick M

1 reference

19 October 2017

Wilfert C

1 reference

19 October 2017

McKinney R Jr

1 reference

19 October 2017

Crain MJ

1 reference

19 October 2017

Elkins MM

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 January 1993

1 reference

The Journal of Pediatrics

19 October 2017

published in

1 reference

19 October 2017

volume

122

1 reference

19 October 2017

1 reference

19 October 2017

page(s)

137-144

1 reference

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

A general model of metabolite kinetics following intravenous and oral administration of the parent drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

The pharmacokinetics of zidovudine administered by continuous infusion in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983507-3

10.1016/S0022-3476(05)83507-3

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference